ID Source | ID |
---|---|
PubMed CID | 14220 |
CHEMBL ID | 2107104 |
SCHEMBL ID | 514842 |
MeSH ID | M0216531 |
Synonym |
---|
AKOS009031612 |
LS-13209 |
methionine methylsulfonium chloride, dl- |
(3-carboxy-3-aminopropyl)dimethylsulfonium chloride |
einecs 222-484-4 |
(3-amino-3-carboxypropyl)dimethylsulfonium chloride, dl- |
sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, (+-)- |
methionylmethylsulfonium chloride |
sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride |
sulfonium, (3-carboxy-3-aminopropyl)dimethyl-, chloride |
(1)-(3-amino-3-carboxypropyl)dimethylsulphonium chloride |
methylmethionine sulfonium chloride, dl- |
ai3-63159 |
fema no. 3445 |
NCGC00167557-01 |
dl-methionine methylsulfonium chloride, >=99.0% (at) |
M0644 |
3493-12-7 |
vitamin u chloride |
s-methylmethioninesulfonium chloride |
dl-methionine methylsulfonium chloride |
(3-amino-3-carboxypropyl)dimethylsulfonium chloride |
dtxcid4026713 |
dtxsid6046713 , |
tox21_112552 |
cas-3493-12-7 |
CHEMBL2107104 |
sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride (1:1) |
unii-5q59i6h55o |
5q59i6h55o , |
FT-0671136 |
FT-0625490 |
sulfonium, (3-amino-3-carboxypropyl)dimethyl-, chloride, (+/-)- |
vitas-u |
methylmethionine chloride, dl- |
s-methylmethionine dl-form chloride [mi] |
dl-methionine methylsulphonium chloride |
cabagin-u |
.gamma.-dimethylsulfonium-.alpha.-aminobutyric acid chloride |
dl-(3-amino-3-carboxypropyl)dimethylsulfonium chloride [fhfi] |
SCHEMBL514842 |
s-methylmethionine sulfonium chloride; u-vi |
mfcd00031700 |
l-methionine-d3 (s-methyl-d3)-methyl-d3 sulfonium chloride |
CCG-266581 |
dl-methylmethionine chloride |
Q27262729 |
CS-0083177 |
HY-N6655 |
dl-methionine methylsulfonium (chloride) |
(3-amino-3-carboxypropyl)-dimethylsulfanium;chloride |
dl-methionine methylsulfoniuym chloride |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 39.8107 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (9.09) | 24.3611 |
2020's | 9 (81.82) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (9.09%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |